A new study quantifying industry involvement in the ultra-processed food debate has found that about nine in ten published papers disputing the category’s definition had authors with food industry ties. For an industry whose products fill the category in question, the finding is commercially significant: definitions drive regulation, regulation drives reformulation and labelling costs, and the scientific argument over a definition is therefore also a business contest.
The study’s authors are careful to separate two claims. The first is factual — the funding pattern exists and is heavily one-sided. The second, which they do not make, would be that industry-linked papers are necessarily incorrect. The classification under attack, NOVA, has documented weaknesses that independent scientists also criticise. The business question is different: how much of the visible scepticism would exist without an industry paying for its production?
What is being defined, and why it costs money
NOVA, developed by University of São Paulo researchers, classifies foods by degree of processing. Its fourth group — soft drinks, snacks, confectionery, instant products and many ready meals — constitutes a large share of supermarket revenue in developed markets. If regulators adopt NOVA-style categories for front-of-pack warnings, taxes or marketing restrictions, manufacturers face reformulation programmes, packaging changes and potential sales losses.
Some countries have already moved: warning labels based partly on processing and nutrient thresholds operate in parts of Latin America, and their effects on purchasing are being studied by bodies including the World Health Organization. Each new jurisdiction that adopts such rules raises the value, to industry, of scientific arguments that the underlying definition is unsound.
The economics of doubt
Scholars of corporate influence describe a familiar playbook, refined in the tobacco era: fund research that emphasises complexity, highlight genuine uncertainties, and present the resulting literature as evidence that the science is unsettled. No individual paper needs to be wrong; the aggregate effect is delay, and delay has a cash value when regulation is the alternative.
Journals now require conflict-of-interest disclosures, and this study essentially aggregates those disclosures into a balance sheet of the debate. Its implication for executives is double-edged. Legitimate scientific engagement is defensible and often valuable; a literature perceived as bought invites regulators and journalists to discount industry positions wholesale — including the sound ones. The Harvard T.H. Chan School of Public Health and other academic institutions increasingly model the alternative: pooled, independently governed research funding.
The boardroom takeaway
For boards, the study converts an academic argument into a governance question. Research strategy is rarely reviewed at board level, yet the reputational exposure it creates plainly belongs there: a single audit, reported in a paragraph, can recast years of sponsored scepticism as a liability in front of regulators and consumers alike. Companies with long brand horizons have the most to lose from that recasting, and the most to gain from research relationships that can survive daylight.
The direction of the market reinforces the point. Retailers are building their own nutrition standards into shelf placement, insurers and employers are experimenting with food-as-medicine programmes, and several jurisdictions are tightening labelling regardless of how the academic debate ends. Against that backdrop, the cheapest strategy is rarely the one that defers the inevitable; it is the one that adapts the portfolio early and funds science nobody has to discount.
What companies and consumers should take from it
For food businesses, the strategic reading is that definition risk is now a line item. Labelling decisions in the United States rest with the US Food and Drug Administration, and the direction of travel internationally favours clearer processing signals to shoppers. Companies investing early in reformulation and transparent research relationships are buying insurance against the day the definition argument ends — however it ends.
For consumers, the study changes little about the underlying dietary evidence, which remains largely observational and contested at the margins, and it would be a mistake to treat it as proof of specific harms. Its real lesson is about information markets: when ninety percent of the criticism of a label comes from those the label would affect, scepticism toward the sceptics is rational. Our coverage of research and regulation in this recent article and this related explainer returns to the same theme — follow the funding, then read the findings.
